Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of hypofractionated radiotherapy plus GM-CSF, pomalidomide, and glofitamab in newly diagnosed primary CNS diffuse large B-cell lymphoma
ChiCTR2600131924Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab, pomalidomide and sargramostim in Diffuse Large B-Cell Primary Central Nervous System Lymphoma, sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete Remission Rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
glofitamabpomalidomidesargramostim
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on ChiCTR2600131924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131924.